{
    "Clinical Trial ID": "NCT02441946",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Abemaciclib + Anastrozole",
        "  Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.",
        "  All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an additional 14 weeks.",
        "  Total treatment duration was 16 weeks.",
        "INTERVENTION 2: ",
        "  Abemaciclib",
        "  Participants received 150 mg of abemaciclib orally Q12H for 2 weeks.",
        "  All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole QD for an additional 14 weeks.",
        "  Total treatment duration was 16 weeks."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Have postmenopausal status.",
        "  Adenocarcinoma of the breast.",
        "  Breast tumor 1 centimeter (cm) in diameter, HR+, HER2-.",
        "  Neoadjuvant endocrine monotherapy is deemed to be a suitable therapy.",
        "  Primary breast cancer that is suitable for baseline core biopsy.",
        "  Have adequate organ function.",
        "Exclusion Criteria:",
        "  Bilateral invasive breast cancer.",
        "  Metastatic breast cancer (local spread to axillary lymph nodes is permitted).",
        "  Inflammatory breast cancer.",
        "  Prior systemic therapy or radiotherapy for invasive or non-invasive breast cancer in the same breast as currently being treated.",
        "  Prior radiotherapy to the ipsilateral chest wall for any malignancy.",
        "  Prior anti-estrogen therapy."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percent Change From Baseline to 2 Weeks in Ki67 Expression",
        "  Tumor tissue collected through a core biopsy at baseline and at the end of cycle 1 was used to determine Ki67 expression. Ki67 expression is defined as the percent of cells staining positive by validated central assay.",
        "  Time frame: Baseline, 2 Weeks",
        "Results 1: ",
        "  Arm/Group Title: Abemaciclib + Anastrozole",
        "  Arm/Group Description: Participants were given 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for 2 weeks.",
        "  All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole orally QD for an additional 14 weeks.",
        "  Total treatment duration was 16 weeks.",
        "  Overall Number of Participants Analyzed: 59",
        "  Geometric Mean (90% Confidence Interval)",
        "  Unit of Measure: Percent Change  -92.86        (-94.82 to -90.16)",
        "Results 2: ",
        "  Arm/Group Title: Abemaciclib",
        "  Arm/Group Description: Participants received 150 mg of abemaciclib orally Q12H for 2 weeks.",
        "  All participants received 150 mg of abemaciclib orally Q12H plus 1 mg of anastrozole QD for an additional 14 weeks.",
        "  Total treatment duration was 16 weeks.",
        "  Overall Number of Participants Analyzed: 52",
        "  Geometric Mean (90% Confidence Interval)",
        "  Unit of Measure: Percent Change  -90.52        (-93.12 to -86.93)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/74 (1.35%)",
        "  Neutropenia 0/74 (0.00%)",
        "  Acute coronary syndrome 0/74 (0.00%)",
        "  Angina pectoris 0/74 (0.00%)",
        "  Myocardial infarction 0/74 (0.00%)",
        "  Abdominal pain 1/74 (1.35%)",
        "  Pancreatitis 0/74 (0.00%)",
        "  Mastitis 0/74 (0.00%)",
        "  Fracture 0/74 (0.00%)",
        "  Alanine aminotransferase increased 1/74 (1.35%)",
        "  Aspartate aminotransferase increased 1/74 (1.35%)",
        "Adverse Events 2:",
        "  Total: 1/75 (1.33%)",
        "  Neutropenia 0/75 (0.00%)",
        "  Acute coronary syndrome 0/75 (0.00%)",
        "  Angina pectoris 0/75 (0.00%)",
        "  Myocardial infarction 0/75 (0.00%)",
        "  Abdominal pain 0/75 (0.00%)",
        "  Pancreatitis 0/75 (0.00%)",
        "  Mastitis 0/75 (0.00%)",
        "  Fracture 0/75 (0.00%)",
        "  Alanine aminotransferase increased 0/75 (0.00%)",
        "  Aspartate aminotransferase increased 0/75 (0.00%)"
    ]
}